

Nobuo Okabe,\* Yasunori  
Muranishi and Mamiko Odoko

Faculty of Pharmaceutical Sciences, Kinki  
University, Kowakae 3-4-1, Higashiosaka,  
Osaka 577-8502, Japan

Correspondence e-mail:  
okabe@phar.kindai.ac.jp

#### Key indicators

Single-crystal X-ray study

$T = 296\text{ K}$

Mean  $\sigma(\text{C}-\text{C}) = 0.007\text{ \AA}$

H-atom completeness 85%

$R$  factor = 0.053

wR factor = 0.176

Data-to-parameter ratio = 17.3

For details of how these key indicators were  
automatically derived from the article, see  
<http://journals.iucr.org/e>.

## Bis(8-hydroxyquinolinato)oxopropoxovanadium(V)

The title compound,  $[\text{VO}(\text{C}_9\text{H}_6\text{NO})_2(\text{C}_3\text{H}_7\text{O})]$ , contains a six-coordinate  $\text{V}^{\text{V}}$  atom. The central  $\text{V}^{\text{V}}$  atom has a distorted octahedral coordination geometry involving two O atoms of the oxo ( $\text{V}=\text{O}$ ) and propoxo ( $\text{V}-\text{O}^i\text{Pr}$ ) groups, two N and two O atoms of the two 8-hydroxyquinoline rings.


Received 22 January 2002

Accepted 4 February 2002

Online 8 February 2002


#### Comment

8-Hydroxyquinoline (8-quinolinol, oxine) is a well known analytical reagent for forming chelate complexes with metal ions. Its metal complexes with copper(II), zinc(II) and nickel(II) have remarkable antimicrobial or fungicidal activity (Okide *et al.*, 2000; Patel *et al.*, 1999). The bismuth(III) complex also has antitumor activity against leukemia (Smith *et al.*, 1998). On the other hand, vanadium(IV) and vanadium(V) salts have insulin-mimetic effects in living animals (Bhattacharyya & Tracey, 2001) or in intact cell systems (Kanamori *et al.*, 2001). Peroxovanadium(V) complexes also show anti-tumor activity (Djordjevic & Wampler, 1985). These findings drive the structural research on various 8-hydroxyquinoline derivatives, as well as vanadium compounds, because of their therapeutic value. For these reasons, we aimed to prepare compounds of 8-hydroxyquinoline and vanadium, and determine their structures.



(I)

Here, we report the structure of a vanadium(V) complex of 8-hydroxyquinoline, (I). The molecular structure of (I) is shown in Fig. 1. The crystal structures of similar vanadium(V) compounds have been reported, *e.g.* as the isopropyl ester, oxoisopropobis(8-hydroxyquinolinato)vanadium(V) with a  $\text{VO}(\text{O}^i\text{Pr})$  group (Scheidt, 1973), and as the ethyl ester, oxoethobis(5,7-dichloro-8-hydroxyquinolinato)vanadium(V) with a  $\text{VO}(\text{OEt})$  group (González-Baró *et al.*, 1998). These species are considered to be inorganic esters (Baran, 2000). Both of the above esters were prepared by the esterification of oxohydroxobis(8-hydroxyquinolinato)vanadium(V)



**Figure 1**  
ORTEPII (Johnson, 1976) drawing of the title compound with the atomic numbering scheme. Displacement ellipsoids for non-H atoms correspond to 50% probability.

and oxohydroxobis(5,7-dichloro-8-hydroxyquinolino)vanadium(V).

The O atoms of the oxo ( $V=O$ ) and propoxo ( $V-O^iPr$ ) groups are in a *cis* configuration with respect to the  $VO(O^iPr)$  group. Two N atoms of the 8-hydroxyquinoline molecules are located in mutually *cis* positions, but two O atoms at the 8-position are *trans*. The central V atom has a distorted octahedral coordination geometry. The overall atomic arrangement of the title compound is the same as in oxoisopropoxo(8-hydroxyquinolino)vanadium(V) (Scheidt, 1973), although there are small differences in their geometrical parameters.

## Experimental

A dark-brown plate-shaped crystal of (I) was obtained by slow evaporation from a propanol solution of a mixture of 8-hydroxyquinoline and  $VOSO_4$  (8:1).

### Crystal data

$C_{21}H_{19}N_2O_4V$   
 $M_r = 414.33$   
 Triclinic,  $P\bar{1}$   
 $a = 9.639$  (3) Å  
 $b = 12.751$  (3) Å  
 $c = 9.044$  (3) Å  
 $\alpha = 95.76$  (2)°  
 $\beta = 110.97$  (2)°  
 $\gamma = 108.63$  (2)°  
 $V = 954.1$  (5) Å<sup>3</sup>

$Z = 2$   
 $D_x = 1.442$  Mg m<sup>-3</sup>  
 Mo  $K\alpha$  radiation  
 Cell parameters from 25 reflections  
 $\theta = 14.7$ – $15.0$ °  
 $\mu = 0.55$  mm<sup>-1</sup>  
 $T = 296.2$  K  
 Hexagonal plate, dark brown  
 $0.20 \times 0.20 \times 0.07$  mm

### Data collection

Rigaku AFC-5R diffractometer  
 $\omega$ - $2\theta$  scans  
 Absorption correction:  $\psi$  scan  
 (North *et al.*, 1968)  
 $T_{min} = 0.896$ ,  $T_{max} = 0.962$   
 4645 measured reflections  
 4391 independent reflections  
 2952 reflections with  $I > 2\sigma(I)$

$R_{int} = 0.018$   
 $\theta_{max} = 27.5$ °  
 $h = 0 \rightarrow 12$   
 $k = -16 \rightarrow 15$   
 $l = -11 \rightarrow 10$   
 3 standard reflections  
 every 150 reflections  
 intensity decay: 0.6%

### Refinement

Refinement on  $F^2$   
 $R[F^2 > 2\sigma(F^2)] = 0.053$   
 $wR(F^2) = 0.176$   
 $S = 1.14$   
 4389 reflections  
 253 parameters

H-atom parameters constrained  
 $w = 1/[\sigma^2(F_o^2) + (0.1P)^2]$   
 where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{max} = -0.002$   
 $\Delta\rho_{max} = 0.64$  e Å<sup>-3</sup>  
 $\Delta\rho_{min} = -0.43$  e Å<sup>-3</sup>

**Table 1**

Selected geometric parameters (Å, °).

V1–O1A	1.924 (3)	V1–N1B	2.307 (3)
V1–O1B	1.888 (3)	O1A–C8A	1.328 (4)
V1–O1V	1.600 (3)	O1B–C8B	1.338 (5)
V1–O2V	1.775 (2)	O2V–C1P	1.420 (6)
V1–N1A	2.207 (3)		
O1A–V1–O1B	153.0 (1)	O1V–V1–N1B	169.6 (1)
O1A–V1–O1V	103.0 (1)	O2V–V1–N1A	164.8 (1)
O1A–V1–O2V	93.7 (1)	O2V–V1–N1B	86.4 (1)
O1A–V1–N1A	76.9 (1)	N1A–V1–N1B	80.52 (10)
O1A–V1–N1B	82.1 (1)	V1–O1A–C8A	120.8 (2)
O1B–V1–O1V	96.2 (1)	V1–O1B–C8B	123.0 (2)
O1B–V1–O2V	100.6 (1)	V1–O2V–C1P	129.7 (2)
O1B–V1–N1A	83.8 (1)	V1–N1A–C1A	130.5 (3)
O1B–V1–N1B	76.2 (1)	V1–N1A–C9A	111.2 (2)
O1V–V1–O2V	102.1 (1)	V1–N1B–C1B	132.9 (3)
O1V–V1–N1A	91.7 (1)	V1–N1B–C9B	108.5 (2)
V1–O1A–C8A–C7A	173.7 (3)	O1V–V1–O1B–C8B	–174.3 (2)
V1–O1B–C8B–C7B	–178.1 (2)	O1V–V1–O2V–C1P	–4.6 (4)
V1–O2V–C1P–C2P	–91.6 (5)	O2V–C1P–C2P–C3P	0 (1)
O1A–V1–O2V–C1P	–108.7 (4)	N1A–V1–O1B–C8B	–83.2 (2)
O1A–V1–N1B–C1B	–16.9 (3)	N1B–V1–O1A–C8A	–78.1 (2)
O1B–V1–O2V–C1P	94.2 (4)	N1B–V1–O2V–C1P	169.4 (4)
O1V–V1–O1A–C8A	92.7 (3)		

All H atoms, except those attached to C3P, were located in difference Fourier maps; they were then fixed at ideal positions and included in the refinement as riding atoms.

Data collection: *MSC/AFCDiffractometer Control Software* (Molecular Structure Corporation and Rigaku Corporation, 1999); cell refinement: *MSC/AFCDiffractometer Control Software*; data reduction: *TEXSAN* (Molecular Structure Corporation and Rigaku Corporation, 1999); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997) and *DIRDIF94* (Beurskens *et al.*, 1994); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPII* (Johnson, 1976); software used to prepare material for publication: *TEXSAN*.

## References

- Baran, E. J. (2000). *J. Inorg. Biochem.* **80**, 1–10.  
 Beurskens, P. T., Admiraal, G., Beurskens, G., Bosman, W. P., de Gelder, R., Israel, R. & Smits, J. M. M. (1994). *The DIRDIF94 Program System*. Technical Report, Crystallography Laboratory, University of Nijmegen, The Netherlands.  
 Bhattacharyya, S. & Tracey, A. S. (2001). *J. Inorg. Biochem.* **85**, 9–13.  
 Djordjevic, C. & Wampler, G. L. (1985). *J. Inorg. Biochem.* **25**, 51–55.  
 González-Baró, A. C., Piro, O. E., Parajón-Costa, B. S., Baran, E. J. & Castellano, E. E. (1998). *Monatsh. Chem.* **129**, 31–39.  
 Johnson, C. K. (1976). *ORTEPII*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.  
 Kanamori, K., Nishida, K., Miyata, N., Okamoto, K., Miyoshi, Y., Tamura, A. & Sakurai, H. (2001). *J. Inorg. Biochem.* **86**, 649–656.  
 Molecular Structure Corporation & Rigaku Corporation (1999). *MSC/AFCDiffractometer Control Software* and *TEXSAN* (Version 1.10). MSC, 9009

- New Trails Drive, The Woodlands, TX 77381-5209, USA, and Rigaku, 3-9-12 Akishima, Tokyo, Japan.
- North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst. A* **24**, 351–359.
- Okide, G. B., Adikwu, M. & Esimone, C. O. (2000). *Biol. Pharm. Bull.* **23**, 257–258.
- Patel, A. K., Patel, V. M., Patel, R. A., Sharma, S., Vora, J. J. & Joshi, J. D. (1999). *Synth. React. Inorg. Met. Org. Chem.* **29**, 193–204.
- Scheidt, W. R. (1973). *Inorg. Chem.* **12**, 1758–1761.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Smith, K. A., Deacon, G. B., Jackson, W. R., Tiekink, E. R. T., Rainone, S. & Webster, L. K. (1998). *Met. Based Drugs*, **5**, 295–304.